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The two main reasons for death of cancer patients, tumor recurrence and metastasis, are
multi-stage cellular processes that involve increased cell plasticity and coincide with ele-
vated resistance to anti-cancer treatments. Epithelial-to-mesenchymal transition (EMT) is a
key contributor to metastasis in many cancer types, including thyroid cancer and is known
to confer stem cell-like properties onto cancer cells. This review provides an overview
of molecular mechanisms and factors known to contribute to cancer cell plasticity and
capable of enhancing cancer cell resistance to radio- and chemotherapy. We elucidate
the role of DNA repair mechanisms in contributing to therapeutic resistance, with a spe-
cial emphasis on thyroid cancer. Next, we explore the emerging roles of autophagy and
damage-associated molecular pattern responses in EMT and chemoresistance in tumor
cells. Finally, we demonstrate how cancer cells, including thyroid cancer cells, can highjack
the oncofetal nucleoprotein high-mobility group A2 to gain increased transformative cell
plasticity, prevent apoptosis, and enhance metastasis of chemoresistant tumor cells.
Keywords: thyroid cancer, therapeutic resistance, stem cells, HMGA2, DAMP, autophagy, ER stress, DNA repair
INTRODUCTION
Tissue invasion, metastasis, as well as radio- and chemotherapeutic
resistance to anti-cancer treatments are common and main causes
of death in cancer patients. Tumor cells mount complex and still
poorly understood molecular defense mechanisms to counteract
and evade oxygen deprivation, nutritional restrictions, as well as
radio- and chemotherapeutic treatment regimens aimed at desta-
bilizing their genomes and important cellular processes. In thyroid
cancer, as in other tumors, such defense strategies include the reac-
tivation in cancer cells of early developmental programs normally
active exclusively in stem cells, the stimulation of cancer stem-like
cells resident within the tumor tissue, and the recruitment of bone
marrow-derived progenitors into the tumor (1–3). Metastasis and
therapeutic resistance in cancer (stem) cells involve the epithelial-
to-mesenchymal transition (EMT)-mediated enhancement in cel-
lular plasticity, which includes coordinated dynamic biochemical
and nuclear changes (4). The purpose of the present review is to
provide an overview of the role of DNA repair mechanisms con-
tributing to radio- and chemotherapeutic resistance in cancer with
an emphasis on thyroid cancer and highlight the emerging roles
of autophagy and damage-associated molecular pattern (DAMP)
responses in EMT and chemoresistance in tumor cells. Finally, we
use the stem cell factor and nucleoprotein high-mobility group
A2 (HMGA2) as an example to demonstrate how factors intended
to protect stem cells are wielded by cancer (stem) cells to gain
increased transformative cell plasticity, which enhances metastasis,
chemotherapeutic resistance, and cell survival. Wherever possible,
we have included information on these cellular processes and
associated factors as they relate to thyroid cancer cells.
THYROID CANCER: HIGH INCIDENCE AND NEWWAYS TO
PREDICT RISK OF DEATH
Thyroid cancer is the most common malignant endocrine tumor
and the seventh most common cancer seen in Canadians account-
ing for 11% of all cancers in women <40 years. In Canada, the
incidence of thyroid cancer is increasing more rapidly than any
other cancer; by 6.8% per year in Canadian males (1998–2007)
and by 6.9% per year in Canadian females (2002–2007) (5). A
373% increase in the incidence of thyroid cancer was reported in a
population-based cohort in Canada (6). The trends in the United
States (US) mirror that of Canada,with an increase in the incidence
of thyroid cancer from 4.85/100,000 in 1975 to 14.25/100,000 in
2009 and an annual percent increase (2000–2009) of 6.0% for the
US males and 6.9% for the US females (7). The life time proba-
bility of developing a thyroid cancer for a Canadian female is 1
in 71 (1.4%) but only 1 in 1,374 (0.1%) will actually die from
it. Canadian males have a lower lifetime risk of developing thy-
roid cancer at 1 in 223 (0.4%) with the risk of death from thyroid
cancer at 1 in 1,937 (0.1%) (8). Although the incidence of thyroid
cancer has been rising, this tumor has an excellent 5-year rela-
tive survival ratio of 98% in 2011 (8). Thyroid cancer represents
a conglomerate of different histological types with diverse clinical
behavior. Over 90% of all thyroid cancers are either follicular or
papillary carcinoma, termed differentiated thyroid cancer (DTC),
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and carry excellent prognosis. By contrast, poorly differentiated
and anaplastic thyroid cancers (ATC) have a very poor outcome.
Surgery and/or radioactive iodine exposure is the mainstay of
treatment for DTC. ATC are usually diagnosed at an advanced
stage when surgery is not feasible and radiation and chemother-
apy are the only option. Thyroid cancer stem cell populations have
been described for both DTC and ATC (2, 9–11). The histology
and age of the patient at diagnosis are two principal determinants
of thyroid cancer-specific survival. The improvement in the thy-
roid cancer-specific survival over the last four decades is largely
attributed to the declining proportion of ATC (12). An age thresh-
old of 45 years at the time of diagnosis of DTC used by the TNM
classification system of the American Joint Committee on Cancer
and International Union against Cancer (TNM-AJCC/IUCC) for
stratification into low- and high-risk thyroid cancers has been
questioned and an alternative age cut off of 55 years was suggested
(13). To predict an individual’s risk of death from thyroid cancer
within 10 years of diagnosis, we recently developed a prognostic
nomogram which accounts for the patient’s age and gender, TNM
stage and histology, and the presence of post-treatment macro-
scopic residual disease as important independent determinants of
thyroid cancer-specific survival (12).
MECHANISMS OF THERAPY RESISTANCE IN THYROID
CANCER
DNA REPAIR MECHANISMS
Mechanisms involved in single-stranded [base excision repair
(BER), nucleotide excision repair (NER), mismatch repair
(MMR)] and double-stranded [homologous recombination (HR),
non-homologous end-joining (NHEJ)] DNA repair significantly
affect the ability of thyroid cancer (stem) cells to counteract and
survive radio- and chemotherapy. Here, we focus on factors and
their polymorphic genotypes that are involved in specific DNA
repair pathways and have been shown to affect the incidence of
thyroid cancer.
The multistep BER pathway is the main mechanism respon-
sible for the replacement of individual DNA bases that have
been altered by alkylation, oxidation, and deamination [for
review see Ref. (14)]. The damaged base is recognized by spe-
cific DNA glycosylases like OGG1, which recognizes and excises
8-oxoguanine to generate an apurinic/apyrimidinic (AP) abasic
site. Loss of heterozygosity (LOH) of the glycosylase OGG1 is
strongly associated with papillary thyroid cancer (PTC) (15). The
apurinic/apyrimidinic endonuclease 1 (APE1) recognizes the AP
site and cleaves the phosphodiester bond at the 5′ end to yield a
3′-OH nucleotide and 5′-deoxyribose phosphate (dRp) terminus.
The 5′-dRp site is cytotoxic and conversion into an inert 3′-OH
requires lyase activity provided by BER-associated APE1, DNA
polymerase β (PolB), and stem cell nucleoprotein members high-
mobility group A1 and A2 (HMGA1/2) (16). Presence of HMGA1
and/or HMGA2 confers enhanced BER capacity and chemore-
sistance against alkylating agents onto thyroid cancer cells (16,
17). The scaffolding protein X-ray repair cross-complementing
group 1 (XRCC1) facilitates the assembly of the PolB–DNA
ligase III–PARP complex and the formation of phosphodiester
bonds to complete the BER repair of AP sites (18). Investigations
into the possible association of XRCC1 Arg399Gln, Arg280His,
and Arg194Trp polymorphisms with thyroid cancer revealed that
hetero- and homozygous XRCC1 Arg399Gln polymorphism coin-
cided with a decreased risk of DTC in the Caucasian population
and mixed population (19–22). The XRCC1 Arg280His polymor-
phism enhanced susceptibility of DTC in Caucasians but protect
against DTC in Asians (21, 23), whereas a homozygous XRCC1
Arg194Trp polymorphic genotype may increase the risk of PTC
and lymphatic metastasis (19, 20, 24, 25).
The ERCC2 DNA helicase is a member of the NER pathway and
contributes to the repair of distorted DNA regions due to bulky
DNA adducts and UV light-induced DNA damage [for review see
Ref. (26)]. The ERCC2 G23591A gene polymorphism results in
an Asp312Asn mutation in a conserved region and the A35931C
polymorphism causes a Lys751Gln substitution. Both polymor-
phisms are in linkage equilibrium and those patients homozygous
for both rare variant alleles show an increased risk for PTC but not
follicular thyroid cancer (FTC) (27).
The MMR pathway eliminates mismatched bases and incorrect
insertions/deletions as a result of faulty DNA replication. The het-
erodimer of MutS complex (MSH2 pairing with MSH6 and MSH3,
respectively) locks onto the base mismatch and recruits het-
erodimeric endonuclease MutL, composed of PMS2 and MLH1,
and the exonuclease 1 (EXO1) to remove the mismatched base.
The abasic gap is filled and ligated by DNA polymerase δ/ε and
DNA ligase, respectively (28). Higher expression of MLH1, MSH2,
and PMS1 were observed in malignant thyroid tumors than in
benign lesions (29). BRAF V600E mutations, RET/PTC rearrange-
ments, and transitions (IDH1 and NRAS) are associated with low
expression of MLH1 in thyroid cancer patients (30).
Genotoxic ionizing radiation and DNA-damaging agents can
cause double-strand breaks (DSBs). This triggers DNA DSB repair
in the form of either HR or NHEJ (31). HR uses a sister chro-
matid template and thus functions in late G2–S cell cycle phase.
HR is a highly accurate and error-free repair process [for review
see Ref. (28, 31, 32)]. Radiation-induced thyroid tumors are
the direct result of radiation-related DSBs and chromosomal
rearrangements (33–35). In the Saudi Arabian population, the
RAD52 Gln221Glu polymorphic genotype and RAD52 2259C>T
genotype, and variants thereof carrying a T allele, were reported
to have a significantly higher risk of developing thyroid cancer
(36). Two other studies identified the combinations of RAD52
2259C>T, XRCC2 R188H and XRCC3 T241M polymorphisms
(37) and RAD51 Exon1/59G>T, XRCC3 Thr241Met variant alle-
les to have predictive value for the polygenic risk of thyroid
cancer (19).
Non-homologous end-joining is a DSB repair that does not
require homologous DNA as a template and, thus, functions
throughout the cell cycle [for review see Ref. (38–40)]. The
Ku70/80 protein complex recognizes DSBs and participates in
the recruitment of DNA-dependent protein kinases. The human
pituitary tumor transforming gene (PTTG) is highly expressed in
human thyroid carcinoma and binds to and inhibits Ku70 pro-
tein. Suppression of PTTG gene expression coincides with an
up-regulation of DNA repair proteins in thyroid cancer suggest-
ing a role for PTTG in therapeutic resistance (41–45). XRCC7 is
another NHEJ factor and XRCC7 Ile3434Thr polymorphism has
recently been associated with increased incidence of DTC (46).
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ENDOPLASMIC RETICULUM STRESS, AUTOPHAGY, AND
EPITHELIAL-TO-MESENCHYMAL TRANSITION
ENDOPLASMIC RETICULUM STRESS AND EPITHELIAL MESENCHYMAL
TRANSITION
Unfolded protein response (UPR) pathways are activated to offset
the adverse effects of protein accumulation in the endoplasmic
reticulum (ER), following the induction of ER stress [reviewed
in Ref. (47)]. Activating transcription factor 6 (ATF6), inositol-
requiring protein-1 (IRE1), and PKR-like ER kinase (PERK) con-
stitute the three arms of the UPR which control specific regulatory
mechanisms to ease protein translation, regulate metabolism rate
and redox events, augment expression of protein-folding chaper-
ones, and increase the production of protein degradation enzymes
(48, 49). The first step of UPR activation includes GRP78 chap-
erone dissociation from ER membrane-spanning UPR receptor
proteins, PERK, IRE1, and ATF6 (UPR arms), to facilitate pro-
tein refolding [reviewed in Ref. (49)]. Several metabolic and
environmental cues can trigger ER stress induction and initi-
ate UPR pathways. Cancer-related impairment in UPR response
might affect the ability of cells to maintain homeostasis during
ER stress (50). Rapidly growing tumors are highly dependent on
nutrients and oxygen delivered by the tumor vasculature. Acti-
vated ER stress stimulates an adaptive UPR process and helps
cancer (stem) cells to survive. The X-box binding protein-1 (XBP-
1) has an important involvement in UPR-induced cell survival
and is induced via the IRE1 pathway of UPR (47, 51). XBP-1 is
often over-expressed in cancer cells and, importantly, increases
drug resistance by interfering with cell cycle regulation and by
down-regulating tumor apoptotic responses to anti-cancer drugs.
This makes XBP-1 an attractive cellular factor for dedifferentiation
and EMT in breast cancer cells that negatively regulates the orga-
nization of polarized epithelial cells in estrogen-dependent and
-independent breast tumors (52). Intriguingly, ER stress inducers
(thapsigargin and tunicamycin) were shown to increase XBP-
1 splicing in PC-Cl3 thyroid cells, impeding the thyroglobulin
folding process and inducing accumulation of this glycoprotein
in the ER. In the absence of apoptosis, differentiation of PC-
Cl3 cells was inhibited. ER stress inducers also down-regulated
thyroid-specific genes encoding thyroglobulin, thyroperoxidase,
thyroid transcription factors TTF-1, TTF-2, and Pax-8 in these
thyrocytes (53). This coincides with the establishment of a mes-
enchymal, stem-like phenotype consistent with EMT and included
the down-regulation of E-cadherin transcripts, the up-regulation
of mRNAs encoding vimentin,α-smooth muscle actin, the forma-
tion of actin stress fibers, and the loss of trans-epithelial resistance.
All of these EMT events in thyroid cancer cells were stimulated
with thapsigargin and tunicamycin (53). ER stressors likely facil-
itate EMT in different ways. In human kidney proximal tubular
cells, this was shown to involve the induction of GRP78, GRP94,
and phospho-eIF2α with subsequent EMT phenomenon (54).
Thapsigargin and tunicamycin can also deregulate the intracel-
lular Ca2+ metabolism, up-regulate the pleckstrin member T cell
death-associated gene 51 (TDAG51), which sensitizes human kid-
ney proximal tubular cells to mesenchymal transformation via
Wnt signaling and primes these cells for TGF-β1-induced EMT
response (54).
AUTOPHAGY AND EMT
Autophagy is considered a lysosomal degradation pathway respon-
sible for the digestion of intracellular materials and the recy-
cling of damaged cellular organelles (55, 56). Up to now, three
types of autophagy have been described; these including macro-
autophagy, micro-autophagy, and chaperone-mediated autophagy
(CMA). They differ in their physiological functions and the path-
ways involved in their degradation mechanisms. Macro-autophagy
includes a process of engulfing cellular waste in autophagosomes,
which subsequently fuse with lysosomes and form autophagolyso-
somes, whereas micro-autophagy involves the direct uptake of
cytoplasm by lysosomal membranes. CMA is considered the most
selective form of autophagy and has so far only been described in
mammalian cells. CMA involves a chaperone-guided process of
internalization of soluble proteins by lysosomes [reviewed in Ref.
(55, 57, 58)].
Physiologic basal autophagy plays an essential role in cellular
homeostasis. It enables the cells to break down long-lived pro-
teins and tightly regulates organelle turnover. Recycling of ER
and mitochondria prevents ER stress and the accumulation of
reactive oxygen and nitrogen species. During metabolic stress
conditions, autophagy is initiated to sustain cellular energy in
form of adenosine triphosphate (ATP) required for survival (59).
Selective autophagy assists cells to rid themselves of damaged
organelles, toxic protein aggregates (59), and invading microor-
ganisms [reviewed in Ref. (60, 61)]. Autophagy is induced by
an initial membrane nucleation that requires the ULK1 com-
plex, and a class III phosphoinositide 3-kinase (PI3K) com-
plex, which includes Bcl2 proteins member beclin 1 (62, 63).
The isolation membrane selects its cargo and elongates until
its edges fuse to form a double-membrane structure known
as the autophagosome. Two ubiquitin-like conjugation systems,
Atg5–Atg12 and microtubule-associated protein-1 light chain 3-
phosphatidylethanolamine (LC3-II), are essential for the elon-
gation of the isolation membrane to occur (51, 64–66). The
autophagosome matures by fusing with endosomes and lysosomes
to finally form the autophagolysosome where cargo degradation
occurs (32, 67, 68).
Autophagy plays an essential function in tumor progression,
metastasis, and the inhibition of cancer cell death (69, 70). While
EMT promotes several mechanisms facilitating tumor invasive-
ness and increased cancer cell survival under stress conditions
(71, 72), the association between EMT and autophagy in cancer
invasiveness is less clear. Autophagy is involved in the regula-
tion of epithelial plasticity (70). EMT is a form of enhanced
epithelial plasticity and known to increase therapeutic resistance
of cancer cells to cytotoxic agents and/or radiation. A strong
link has recently been demonstrated between EMT, autophagy,
stem-like characteristics, and resistance of cancer cells to cyto-
toxic T cell-induced killing, and targeting autophagy may help
avoid immune resistance in breast cancer (73). Whether cancer
(stem) cells opt for an aggressive phenotype, choose to enter
an inactive state supported by autophagy, or endure cell death
depends on the activation of different intracellular pathways and
specific changes in gene expression profiles upon external stim-
uli (74). The hedgehog signaling pathway is one example of a
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cellular signaling system balancing invasion versus autophagy.
Active hedgehog signaling promotes an aggressive phenotype (75),
while its inhibition activates autophagy (76). Another example
is the activation of 5′ adenosine monophosphate-activated pro-
tein kinase (AMPK) which reduces tumor cell invasion (77)
and induces autophagy in response to genotoxic stress (78) and
nutrient starvation (79). In hepatocarcinoma cells, the induction
of autophagy represses the expression of epithelial markers but
promotes the expression of mesenchymal markers and the acti-
vation of the TGF-β/Smad3-dependent signaling pathway (80).
Importantly, data from numerous cell systems, including thy-
roid cancer, identify autophagy as an important new player in
EMT plasticity, therapeutic resistance, and metastasis. Clearly,
the role of autophagy and ER stress/UPR responses in thyroid
(cancer) stemness is a newly emerging and exiting field with
potentially important innovation in the treatment of thyroid
cancer.
DAMAGE-ASSOCIATED PATTERN RECOGNITION IN CANCER STEM
CELLS
Damage-associated molecular patterns are a group of endoge-
nous molecules acting as danger signals to initiate cellular repair
and survival mechanisms (81, 82). Endogenous soluble mole-
cules released during cell damage, necrosis, and cell stress are
referred to as alarmins (82, 83). DAMP signaling induces an early
immune response involving the innate and adaptive immune sys-
tem, thus, initiating a “sterile inflammatory” reaction (83). In
contrast, pathogen-associated molecular patterns (PAMPs) are
exogenous danger signals derived from pathogens which activate
diverse cellular receptors of the innate immune system to initi-
ate host defense mechanisms (83). DAMPs may be exposed at
the cell surface, e.g., calreticulin (CRT) and heat shock protein 90
(HSP90), or are secreted from cells, e.g., ATP, S100A8/A9 proteins,
and high-mobility group box 1 protein (HMGB1). Secreted by
tumor cells, these factors promote tumor growth and chemoresis-
tance (81, 84–86); for a comprehensive list of DAMPs and their
receptors, see Ref. (85).
Damage-associated molecular patterns act through membrane-
anchored pattern recognition receptors (PRR) which recognize a
structural pattern rather than a specific ligand. Examples for PRR
are the NOD-like receptors (NLRs), toll-like receptors (TLRs), and
the receptor for advanced glycation end products (RAGEs) (21, 87,
88). Several PRR, in particular TLRs and RAGE, are expressed in
cancer cells and share distinct DAMP ligands such as HMGB1 and
S100 proteins (89). In leukocytes or dendritic cells, PRR signaling
results in the release of cytokines (innate immunity) or the initia-
tion of adaptive immune responses. Interestingly, several PRR such
as the TLRs recognize both PAMP and DAMP ligands (83). Also,
DAMPs can interact with PAMPs to activate several PRR (90), sug-
gesting the utilization of common cellular pathways when sensing
exogenous and endogenous dangers.
All TLRs comprise a leucine-rich repeat extracellular domain
responsible for ligand binding and a transmembrane domain
and an intracellular toll/IL-1 receptor (TIR) domain for signal
transduction. Ligand-binding results in the homo- or hetero-
dimerization of TLRs as a requirement for intracellular signaling
(87). Engaging with the intracellular TIR domains of dimer-
ized TLRs are five cytoplasmic adaptor molecules which activate
intracellular signaling, including NF-κB and MAPK pathways.
These intracellular TLR signaling adaptors are myeloid differen-
tiation factor 88 (MyD88), MyD88 adapter-like protein (MAL),
TIR domain-containing adaptor protein inducing interferon-beta
(TRIF), TRIF-related adaptor molecule (TRAM), and sterile α-
and armadillo-motif-containing protein (SARM) [reviewed in
Ref. (82, 91)]. MyD88 is used by all TLRs and was shown to have
a particular role in tumorigenesis (92).
Receptor for advanced glycation end product belongs to the
immunoglobulin-like family of transmembrane receptors (88, 93)
and is expressed in several human cancers (94). The three extra-
cellular domains of RAGE, the V-, C1-, and C2-domain, function
in ligand binding (93). The single transmembrane domain con-
nects to the short cytoplasmic tail of RAGE which interacts with
the cytoplasmic adaptor molecule diaphanous-1 (Dia-1) (95) and
with toll-interleukin 1 receptor domain-containing adaptor pro-
tein (TIRAP) and MyD88; the latter two are also adapters for TLR
2 and 4 (96). Depending on the ligand and cell context, activated
RAGE can signal through multiple signaling pathways, including
extracellular ERK1/2, p38 MAP kinase, Cdc42/Rac-1, c-Jun-NH2-
terminal kinase/stress-activated protein kinase (JNK/SAPK). This
finally results in the activation of NF-κB and the induction of pro-
inflammatory and pro-migratory responses (97). RAGE ligands
include HMGB1, S100/calgranulin proteins, advanced glycation
end products (AGEs), and amyloid β proteins (98). RAGE sig-
naling can be modified by soluble RAGE species. Endogenously
produced soluble RAGE splice variant (esRAGE), unable to insert
into the membrane, is secreted from cells and acts as a decoy for
RAGE ligands (88). Cleavage of the extracellular domains by a
disintegrin and metalloproteinase 10 (ADAM10) releases soluble
RAGE which can also act as scavenger for ligands (99). Unfortu-
nately, soluble RAGE species are not reliable clinical predictors of
outcome in cancer or inflammatory diseases (88). Ligand binding
to RAGE induces RAGE expression in a positive feedback loop
and promotes clustering of RAGE at the cell surface leading to
sustained RAGE signaling by multimeric ligands (97, 100, 101).
In the thyroid gland, RAGE is not expressed in normal follicu-
lar epithelial cells, but its expression is up-regulated in thyroid
epithelial cells of follicular adenoma and thyroid carcinoma (102)
suggesting that hyperactive and neoplastic thyroid cells respond
to DAMPs.
Utilizing HMGB1 as an example, we demonstrate how DAMP–
PRR signaling can influence tumorigenesis and stem cell func-
tions. HMGB1 is a non-histone DNA-binding protein of the
high-mobility group protein family and is composed of two DNA-
binding HMG-box motives and an acidic C-terminus. Originally
described as an exclusively nuclear protein involved in the modu-
lation of gene transcription and chromosomal stability, HMGB1 is
now known to have a cytoplasmic role in regulating autophagy, cell
survival, and EMT (103). HMGB1 is passively released from dead
or injured cells and actively secreted from immune cells and cancer
cells in response to cellular stress signals (83, 103). HMGB1 secre-
tion is modulated by various post-translational modifications and
by secondary messengers such as cytosolic calcium, nitric oxide,
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and reactive oxygen species (ROS) (103). Extracellular HMGB1
binds to several receptors, including TLR2, TLR4, and RAGE
(89), to promote cell migration, proliferation, and differentiation.
Secreted HMGB1 functions in the repair of tissue damage and
chronic inflammation and leads to increased tumor growth and
metastasis, promotes angiogenesis, regulates vascular remodeling,
and enhances stem cell renewal (88, 89, 104). The influence of
HMGB1 on stem/progenitor cells is mediated via RAGE and TLRs
and results in enhanced stem cell functions (104–106).
HMGB1–RAGE–NF-κB signaling promotes neuronal stem cell
proliferation/differentiation (107) and enhances xenograft metas-
tasis via EMT and the activation of MAPK pathways (108).
Astrocyte-derived HMGB1 enhances stem cell recruitment in the
brain during stroke recovery (109, 110). HMGB1–TLR2 signal-
ing via signal transducer and activator of transcription factor 3
(STAT3) and Smad3 activation enhances breast cancer stem cell
self-renewal and increases breast cancer metastasis (104). HMGB1
aids in the recruitment of endothelial precursor cells (EPC)
using RAGE (111) and TLR2/TLR4 in c-kit-positive EPC (112),
thus, contributing to tissue repair and tumor growth. In PTC,
the HMGB1–RAGE interaction increases the expression of the
microRNAs miR221 and miR222 and promotes PTC cell growth
and motility by inhibiting the cell cycle regulator p27kip1 (113).
The role of TLR in cancer is not fully understood. TLR recep-
tor activation by PAMPs and distinct endogenous (DAMPs) signals
has been associated with either tumor promoting or anti-tumor
activities in human cancers (114, 115). Very little information
exists on the function of DAMP–PRR interactions in the thyroid
gland and in thyroid cancer (stem) cells. Normal human and rat
thyroid cells express TLR 2 and TR4. Activation of TLR in the rat
thyroid cell line FRTL-5 induces NF-κB activation and secretion
of the pro-inflammatory cytokines interferon-beta (IFN-β), indi-
cating that the thyroid gland is capable of responding to DAMPs
and PAMPs with the initiation of “sterile inflammatory responses”
to promote proliferation and angiogenesis in the thyroid (116).
In FTC, TLR4 was localized to inflammatory tissue regions sur-
rounding the tumor and TLR4 expression was associated with
metastasis in FTC patients (117). TLR10 polymorphism has been
associated with increased tumor size in patients with PTC (118). In
mouse breast progenitor cells, PAMP ligands of TLR4 enhance cell
proliferation and mammosphere growth (119), whereas similar
activity in intestinal stem cells induces a p53-dependent apoptosis
(120). Also, flagellin–TLR5 signaling in human breast cancer cells
reduces cell proliferation and anchorage-independent growth in
human breast cancer xenografts (121). TLR4 activation was shown
to suppress TGF-beta signaling and promote chemoresistance in
tumor-initiating cells of virus-induced hepatocellular carcinoma
(21). Cancer stem cells may respond to DAMPs differently from
normal stem cells and the nature of the ligand affects the cellular
responses to PRR activation.
In summary, cross talk between different PRR, the activation of
several PRR by the same DAMP, and the response of one PRR to
more than one DAMP altogether suggest that cellular responses to
DAMPs are: (i) (stem) cell-type and tissue-specific, (ii) influenced
by the nature of the cellular stresses, and (iii) affected by the spa-
tial and temporal distribution and concentration of DAMPs. It is
intriguing to speculate that the complex DAMP–PRR system with
its functional roles in cell plasticity, autophagy, and cellular stress
control represents an important and as yet under-valued novel
topic in stem cell research and a potentially lucrative therapeutic
target to manipulate cancer stem cell functions.
HIGH-MOBILITY GROUP A2: A LINK BETWEEN STEMNESS,
EMT, AND CHEMORESISTANCE
The low molecular weight HMGA2, formerly named HMGI-C,
is a member of the HMGA family of non-histone nuclear pro-
tein, which also includes HMGA1 and its splice forms. Structural
analysis of HMGA2 revealed three DNA-binding domains, called
AT-hook motifs, which facilitate binding to AT-rich regions of the
minor groove of B-form DNA (122, 123). Blockage of HMGA2
can prevent the transformation of rat thyroid cells by murine
retroviruses (124). HMGA2 is a marker of stem cells, absent in
most adult tissues, and re-expressed in many cancer (stem) cells
(125–129). HMGA2 binds to the AT-rich G-bands in the chromo-
somes and to centromeres and telomeres of metaphase prepa-
rations (130). Chromosomal rearrangements of both HMGA1
and HMGA2 proteins have been correlated with neoplastic trans-
formation. HMGA2 overexpression, dysregulation, or trunca-
tion has been linked to benign and malignant tumors. This
includes benign mesenchymal tumors (131), uterine leiomy-
omata (127, 132), pituitary adenoma (132), human prolactin-
oma (133), pancreatic cancer (134, 135), retinoblastoma (136),
embryonic rhabdomyosarcoma (80), chondrosarcoma (137), lung
cancer (138), and hepatocellular carcinoma (104). In thyroid
cancer, elevated levels of HMGA2 are considered a molecular
marker to distinguish benign and malignant thyroid neoplasms
(139, 140).
PROTECTIVE ROLES OF HMGA2
Multifunctional HMGA1 and 2 are localized in the nucleus and
regulate transcriptional genes activity, DNA replication, and DNA
repair (141). HMGA2 is a new member of the BER protein
complex and interacts with human AP endonuclease 1 (APE1)
to promote chemoresistance in cancer cells, including human
undifferentiated thyroid cancer cells (16). HMGA1 and 2 serve
as substrate for the phosphatidylinositol 3-kinase-related kinase
(PIKK) family member ataxia telangiectasia mutated (ATM) and
downstream checkpoint kinase 2 (CHK2) which are important
for DNA damage signaling. Upon exposure to genotoxicants,
increased HMGA1/2 expression correlates with increased ATM
expression levels and enhanced cellular DNA damage response
(142, 143). HMGA2 also interacts with ataxia telangiectasia and
Rad3-related kinase (ATR) and HMGA2-mediated activation of
the ATR–checkpoint kinase 1 (CHK1) signaling pathway with
resulting G2/M arrest increases chemoresistance against BER-
inducing genotoxic alkylating agents in human thyroid and other
cancer cells (17). Recently, we showed that HMGA2 plays an
important novel role in protecting the integrity and functionality
of arrested replication forks in cancer cells. HMGA2 preferen-
tially binds with higher affinity to DNA Y- (replication fork) and
X- (Holliday junctions) structures typically observed at replica-
tion forks (45). Binding of HMGA2 to these DNA conformations
protected stalled replication forks from endonuclease digestion
and conferred a survival advantage onto HMGA2+ cancer cells,
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including thyroid cancer cells, when exposed to chemothera-
peutics such as hydroxyurea used in the treatment of cancer
patients (45).
HMGA2 IN STEMNESS AND EMT
Cancer initiating cells (CIC) evade cell death and attenuate the
cytotoxic effects of radio- and chemotherapy by modulating DNA
damage repair mechanisms to promote therapeutic resistance and
tumor recurrence (80, 144). The Lin28–HMGA2–let-7 axis plays a
significant role in promoting EMT, tissue invasion/metastasis, and
therapeutic resistance in cancer cells (21). Ectopically expressed of
the microRNA binding protein, Lin28 down-regulates the miR let-
7 which attenuates the inhibitory let-7-mediated association with
the 3′ untranslated region of HMGA2 mRNA, resulting in the
up-regulation of HMGA2 protein (145). Presence of HMGA2 in
retinoblastoma and pancreatic cancer cells was shown to enhance
cell proliferation and increase stemness (135, 136). HMGA2 also
has a key role in maintaining high self-renewing capacity in
hematopoietic stem cells and this involves the inhibition of the
micro RNA let-7 by Lin28 (146). Let-7 suppresses both H-Ras
and HMGA2 and this causes reduced proliferation and differen-
tiation of breast CIC (44). In addition to the phenotypic and/or
cell surface markers like CD133, CD34, CD90, SOX2, OCT4, and
NANOG, functional markers such as the aldehyde dehydrogenase
(ALDH) activity also determine the stemness in a cancer sub-
population. The inhibition of ALDH activity reduces stemness and
sensitizes CIC to cytotoxic insult (80). Cellular levels of HMGA2
directly correlate with ALDH activity in breast cancer and con-
tribute to tumor migration and resistance toward DNA-damaging
agents (21). HMGA2 is found at the invasive front of the tumor to
promote tissue invasion and tumor recurrence following therapy
(147). HMGA2-induced EMT is promoted by TGF-β signaling
(147) and the pro-inflammatory cytokine oncostatin M (OSM)
(148) which signal via the STAT3 (148), the Ras/MAPK signal-
ing pathway (135), and Twist and Snail, the two key regulators of
EMT and major contributors to metastasis and tumor recurrence
(104, 149). Suppression of Lin28 or HMGA2 increases let-7 and
this reverses EMT and affects the level of therapeutic resistance.
HMGA2+ cancer cells were shown to exhibit resistance against 4
of 11 anti-cancer drugs tested (128).
In conclusion, cancer (stem) cells capable of utilizing HMG
proteins to enhance DNA repair mechanisms in response to
DNA-damaging drugs are likely contributing to therapeutic resis-
tance to anti-cancer treatments in metastatic or recurrent cancers.
Modulation of the EMT, ER stress, and autophagy regulation in
cancer (stem) cells serves as important survival strategy in avoid-
ing apoptosis under nutritional or oxygen deprivation. Similarly,
DAMP signaling via several PRR may serve as another tumor sur-
vival response by controlling cell proliferation, inflammatory, and
autophagy responses in cancer (stem) cells.
REFERENCES
1. Thomas D, Friedman S, Lin RY. Thyroid stem cells: lessons from nor-
mal development and thyroid cancer. Endocr Relat Cancer (2008) 15:51–8.
doi:10.1677/ERC-07-0210
2. Klonisch T, Hoang-Vu C, Hombach-Klonisch S. Thyroid stem cells and cancer.
Thyroid (2009) 19:1303–15. doi:10.1089/thy.2009.1604
3. Derwahl M. Linking stem cells to thyroid cancer. J Clin EndocrinolMetab (2011)
96:610–3. doi:10.1210/jc.2010-2826
4. Ahmed N, Abubaker K, Findlay J, Quinn M. Epithelial mesenchymal transi-
tion and cancer stem cell-like phenotypes facilitate chemoresistance in recur-
rent ovarian cancer. Curr Cancer Drug Targets (2010) 10:268–78. doi:10.2174/
156800910791190175
5. Statistics CCSSSCOC. In: Society CC, editor. Canadian Cancer Statistics 2012.
(2012).
6. Pathak KA, Leslie WD, Klonisch TC, Nason RW. The changing face of thy-
roid cancer in a population-based cohort. Cancer Med (2013) 2:537–44.
doi:10.1002/cam4.103
7. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al.
SEERCancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda,
MD: National Cancer Institute (2012).
8. Mazurat A, Torroni A, Hendrickson-Rebizant J, Benning H, Nason RW, Pathak
KA. The age factor in survival of a population cohort of well-differentiated
thyroid cancer. Endocr Connect (2013) 2:154–60. doi:10.1530/EC-13-0056
9. Lin RY. Thyroid cancer stem cells. Nat Rev Endocrinol (2011) 7:609–16.
doi:10.1038/nrendo.2011.127
10. Ahn SH, Henderson YC, Williams MD, Lai SY, Clayman GL. Detection of thy-
roid cancer stem cells in papillary thyroid carcinoma. J Clin Endocrinol Metab
(2013) 99(2):536–44. doi:10.1210/jc.2013-2558
11. Yun JY, Kim YA, Choe JY, Min H, Lee KS, Jung Y, et al. Expression of cancer
stem cell markers is more frequent in anaplastic thyroid carcinoma compared
to papillary thyroid carcinoma and is related to adverse clinical outcome. J Clin
Pathol (2014) 67:125–33. doi:10.1136/jclinpath-2013-201711
12. Pathak KA, Mazurat A, Lambert P, Klonisch T, Nason RW. Prognostic nomo-
grams to predict oncological outcome of thyroid cancers. J Clin Endocrinol
Metab (2013) 98:4768–75. doi:10.1210/jc.2013-2318
13. Statistics CCSSSCOC. In: Society CC, editor. Canadian Cancer Statistics 2011.
(2011).
14. Dianov GL. Base excision repair targets for cancer therapy. Am J Cancer Res
(2011) 1:845–51.
15. Royer MC, Zhang H, Fan CY, Kokoska MS. Genetic alterations in papil-
lary thyroid carcinoma and Hashimoto thyroiditis: an analysis of hOGG1
loss of heterozygosity. Arch Otolaryngol Head Neck Surg (2010) 136:240–2.
doi:10.1001/archoto.2010.20
16. Summer H, Li O, Bao Q, Zhan L, Peter S, Sathiyanathan P, et al. HMGA2
exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-
damage-induced cytotoxicity during chemotherapy. Nucleic Acids Res (2009)
37:4371–84. doi:10.1093/nar/gkp375
17. Natarajan S, Hombach-Klonisch S, Dröge P, Klonisch T. HMGA2 inhibits apop-
tosis through interaction with ATR-CHK1 signaling complex in human cancer
cells. Neoplasia (2013) 15:263–80. doi:10.1593/neo.121988
18. Horton JK, Watson M, Stefanick DF, Shaughnessy DT, Taylor JA, Wilson SH.
XRCC1 and DNA polymerase beta in cellular protection against cytotoxic DNA
single-strand breaks. Cell Res (2008) 18:48–63. doi:10.1038/cr.2008.7
19. Bastos HN, Antao MR, Silva SN, Azevedo AP, Manita I, Teixeira V, et al.
Association of polymorphisms in genes of the homologous recombination
DNA repair pathway and thyroid cancer risk. Thyroid (2009) 19:1067–75.
doi:10.1089/thy.2009.0099
20. Fard-Esfahani P, Fard-Esfahani A, Fayaz S, Ghanbarzadeh B, Saidi P, Mohabati
R, et al. Association of Arg194Trp, Arg280His and Arg399Gln polymorphisms
in X-ray repair cross-complementing group 1 gene and risk of differentiated
thyroid carcinoma in Iran. Iran Biomed J (2011) 15:73–8.
21. Bao Y, Jiang L, Zhou JY, Zou JJ, Zheng JY, Chen XF, et al. XRCC1 gene polymor-
phisms and the risk of differentiated thyroid carcinoma (DTC): a meta-analysis
of case-control studies. PLoS One (2013) 8:e64851. doi:10.1371/journal.pone.
0064851
22. Hu Z, Hu X, Long J, Su L, Wei B. XRCC1 polymorphisms and differ-
entiated thyroid carcinoma risk: a meta-analysis. Gene (2013) 528:67–73.
doi:10.1016/j.gene.2013.07.005
23. Garcia-Quispes WA, Perez-Machado G, Akdi A, Pastor S, Galofre P, Biarnes
F, et al. Association studies of OGG1, XRCC1, XRCC2 and XRCC3 polymor-
phisms with differentiated thyroid cancer. Mutat Res (2011) 70(9–710):67–72.
doi:10.1016/j.mrfmmm.2011.03.003
24. Chiang FY, Wu CW, Hsiao PJ, Kuo WR, Lee KW, Lin JC, et al. Association
between polymorphisms in DNA base excision repair genes XRCC1, APE1,
Frontiers in Endocrinology | Thyroid Endocrinology March 2014 | Volume 5 | Article 37 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hombach-Klonisch et al. Mechanisms of therapeutic resistance in cancer
and ADPRT and differentiated thyroid carcinoma. Clin Cancer Res (2008)
14:5919–24. doi:10.1158/1078-0432.CCR-08-0906
25. Ryu RA, Tae K, Min HJ, Jeong JH, Cho SH, Lee SH, et al. XRCC1 polymor-
phisms and risk of papillary thyroid carcinoma in a Korean sample. J Korean
Med Sci (2011) 26:991–5. doi:10.3346/jkms.2011.26.8.991
26. Scharer OD. Nucleotide excision repair in eukaryotes.Cold SpringHarb Perspect
Biol (2013) 5:a012609. doi:10.1101/cshperspect.a012609
27. Silva SN, Gil OM, Oliveira VC, Cabral MN, Azevedo AP, Faber A, et al. Associ-
ation of polymorphisms in ERCC2 gene with non-familial thyroid cancer risk.
Cancer Epidemiol Biomarkers Prev (2005) 14:2407–12. doi:10.1158/1055-9965.
EPI-05-0230
28. Iyama T,Wilson DM III. DNA repair mechanisms in dividing and non-dividing
cells. DNA Repair (2013) 12:620–36. doi:10.1016/j.dnarep.2013.04.015
29. Ruschenburg I, Vollheim B, Stachura J, Cordon-Cardo C, Korabiowska M.
Analysis of DNA mismatch repair gene expression and mutations in thyroid
tumours. Anticancer Res (2006) 26:2107–12.
30. Santos JC, Bastos AU, Cerutti JM, Ribeiro ML. Correlation of MLH1 and
MGMT expression and promoter methylation with genomic instability in
patients with thyroid carcinoma.BMCCancer (2013) 13:79. doi:10.1186/1471-
2407-13-79
31. O’Driscoll M, Jeggo PA. The role of double-strand break repair – insights from
human genetics. Nat Rev Genet (2006) 7:45–54. doi:10.1038/nrg1746
32. Klionsky DJ,Abdalla FC,Abeliovich H,Abraham RT,Acevedo-Arozena A,Adeli
K, et al. Guidelines for the use and interpretation of assays for monitoring
autophagy. Autophagy (2012) 8:445–544. doi:10.4161/auto.19496
33. Nikiforov YE, Koshoffer A, Nikiforova M, Stringer J, Fagin JA. Chromosomal
breakpoint positions suggest a direct role for radiation in inducing illegitimate
recombination between the ELE1 and RET genes in radiation-induced thyroid
carcinomas. Oncogene (1999) 18:6330–4. doi:10.1038/sj.onc.1203019
34. Ciampi R, Knauf JA, Rabes HM, Fagin JA, Nikiforov YE. BRAF kinase activation
via chromosomal rearrangement in radiation-induced and sporadic thyroid
cancer. Cell Cycle (2005) 4:547–8. doi:10.4161/cc.4.4.1631
35. Leeman-Neill RJ, Brenner AV, Little MP, Bogdanova TI, Hatch M, Zurnadzy
LY, et al. RET/PTC and PAX8/PPARgamma chromosomal rearrangements in
post-Chernobyl thyroid cancer and their association with iodine-131 radia-
tion dose and other characteristics. Cancer (2013) 119:1792–9. doi:10.1002/
cncr.27893
36. Siraj AK, Al-Rasheed M, Ibrahim M, Siddiqui K, Al-Dayel F, Al-Sanea O, et al.
RAD52 polymorphisms contribute to the development of papillary thyroid
cancer susceptibility in Middle Eastern population. J Endocrinol Invest (2008)
31:893–9.
37. Fayaz S, Karimmirza M, Tanhaei S, Fathi M, Torbati PM, Fard-Esfahani P.
Increased risk of differentiated thyroid carcinoma with combined effects of
homologous recombination repair gene polymorphisms in an Iranian popula-
tion. Asian Pac J Cancer Prev (2013) 14:6727–31. doi:10.7314/APJCP.2013.14.
11.6727
38. Povirk LF. Biochemical mechanisms of chromosomal translocations result-
ing from DNA double-strand breaks. DNA Repair (Amst) (2006) 5:1199–212.
doi:10.1016/j.dnarep.2006.05.016
39. Gospodinov A, Herceg Z. Chromatin structure in double strand break repair.
DNA Repair (Amst) (2013) 12:800–810. doi:10.1016/j.dnarep.2013.07.006
40. Kakarougkas A, Jeggo PA. DNA DSB repair pathway choice: an orchestrated
handover mechanism. Br J Radiol (2014). doi:10.1259/bjr.20130685
41. Romero F, Multon MC, Ramos-Morales F, Dominguez A, Bernal JA, Pintor-
Toro JA, et al. Human securin, hPTTG, is associated with Ku heterodimer, the
regulatory subunit of the DNA-dependent protein kinase. Nucleic Acids Res
(2001) 29:1300–7. doi:10.1093/nar/29.6.1300
42. Kim D, Pemberton H, Stratford AL, Buelaert K, Watkinson JC, Lopes V, et al.
Pituitary tumour transforming gene (PTTG) induces genetic instability in thy-
roid cells. Oncogene (2005) 24:4861–6. doi:10.1038/sj.onc.1208659
43. Saez C, Martinez-Brocca MA, Castilla C, Soto A, Navarro E, Tortolero M,
et al. Prognostic significance of human pituitary tumor-transforming gene
immunohistochemical expression in differentiated thyroid cancer. J Clin
Endocrinol Metab (2006) 91:1404–9. doi:10.1210/jc.2005-2532
44. Chesnokova V, Zonis S, Rubinek T, Yu R, Ben-Shlomo A, Kovacs K, et al. Senes-
cence mediates pituitary hypoplasia and restrains pituitary tumor growth.
Cancer Res (2007) 67:10564–72. doi:10.1158/0008-5472.CAN-07-0974
45. Yu H, Lim HH, Tjokro NO, Sathiyanathan P, Natarajan S, Chew TW, et al.
Chaperoning HMGA2 protein protects stalled replication forks in stem and
cancer cells. Cell Rep (2014) 6(4):684–97. doi:10.1016/j.celrep.2014.01.014
46. Rahimi M, Fayaz S, Fard-Esfahani A, Modarressi MH, Akrami SM, Fard-
Esfahani P. The role of Ile3434Thr XRCC7 gene polymorphism in differentiated
thyroid cancer risk in an Iranian population. Iran Biomed J (2012) 16:218–22.
47. Sovolyova N, Healy S, Samali A, Logue SE. Stressed to death – mechanisms
of ER stress-induced cell death. Biol Chem (2014) 395:1–13. doi:10.1515/hsz-
2013-0174
48. Tanjore H, Cheng DS, Degryse AL, Zoz DF, Abdolrasulnia R, Lawson WE,
et al. Alveolar epithelial cells undergo epithelial-to-mesenchymal transition in
response to endoplasmic reticulum stress. J Biol Chem (2011) 286:30972–80.
doi:10.1074/jbc.M110.181164
49. Deegan S, Saveljeva S, Gorman AM, Samali A. Stress-induced self-cannibalism:
on the regulation of autophagy by endoplasmic reticulum stress. Cell Mol Life
Sci (2013) 70:2425–41. doi:10.1007/s00018-012-1173-4
50. Vandewynckel YP, Laukens D, Geerts A, Bogaerts E, Paridaens A, Verhelst X,
et al. The paradox of the unfolded protein response in cancer. Anticancer Res
(2013) 33:4683–94.
51. Ghavami S, Yeganeh B, Stelmack GL, Kashani HH, Sharma P, Cunnington R,
et al. Apoptosis, autophagy and ER stress in mevalonate cascade inhibition-
induced cell death of human atrial fibroblasts. Cell Death Dis (2012) 3:e330.
doi:10.1038/cddis.2012.61
52. Shajahan AN, Riggins RB, Clarke R. The role of X-box binding protein-1 in
tumorigenicity. Drug News Perspect (2009) 22:241–6. doi:10.1358/dnp.2009.
22.5.1378631
53. Ulianich L, Garbi C, Treglia AS, Punzi D, Miele C, Raciti GA, et al. ER
stress is associated with dedifferentiation and an epithelial-to-mesenchymal
transition-like phenotype in PC Cl3 thyroid cells. J Cell Sci (2008) 121:477–86.
doi:10.1242/jcs.017202
54. Carlisle RE, Heffernan A, Brimble E, Liu L, Jerome D, Collins CA, et al.
TDAG51 mediates epithelial-to-mesenchymal transition in human proxi-
mal tubular epithelium. Am J Physiol Renal Physiol (2012) 303:F467–81.
doi:10.1152/ajprenal.00481.2011
55. Klionsky DJ, Saltiel AR. Autophagy works out. Cell Metab (2012) 15:273–4.
doi:10.1016/j.cmet.2012.02.008
56. Gong C, Bauvy C, Tonelli G, Yue W, Delomenie C, Nicolas V, et al. Beclin
1 and autophagy are required for the tumorigenicity of breast cancer stem-
like/progenitor cells. Oncogene (2013) 32:2261–72. doi:10.1038/onc.2012.252
57. Arias E, Cuervo AM. Chaperone-mediated autophagy in protein quality con-
trol. Curr Opin Cell Biol (2011) 23:184–9. doi:10.1016/j.ceb.2010.10.009
58. Ghavami S, Shojaei S, Yeganeh B, Ande SR, Jangamreddy JR, Mehrpour M,
et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders.
Prog Neurobiol (2014) 112:24–49. doi:10.1016/j.pneurobio.2013.10.004
59. Mehrpour M, Codogno P. Drug enhanced autophagy to fight mutant protein
overload. J Hepatol (2011) 54:1066–8. doi:10.1016/j.jhep.2010.11.032
60. Mathew R, White E. Why sick cells produce tumors: the protective role of
autophagy. Autophagy (2007) 3:502–5.
61. Yeganeh B, Rezaei Moghadam A, Tran AT, Rahim MN, Ande SR, Hashemi M,
et al. Asthma and influenza virus infection: focusing on cell death and stress
pathways in influenza virus replication. Iran J Allergy Asthma Immunol (2013)
12:1–17. doi:012.01/ijaai.117
62. Levine B, Klionsky DJ. Development by self-digestion: molecular mecha-
nisms and biological functions of autophagy. Dev Cell (2004) 6:463–77.
doi:10.1016/S1534-5807(04)00099-1
63. Ravikumar B, Sarkar S, Davies JE, Futter M, Garcia-Arencibia M, Green-
Thompson ZW, et al. Regulation of mammalian autophagy in physiology and
pathophysiology. Physiol Rev (2010) 90:1383–435. doi:10.1152/physrev.00030.
2009
64. Mizushima N. Autophagy in protein and organelle turnover. Cold Spring Harb
Symp Quant Biol (2011) 76:397–402. doi:10.1101/sqb.2011.76.011023
65. Weidberg H, Elazar Z. TBK1 mediates crosstalk between the innate immune
response and autophagy. Sci Signal (2011) 4:e39. doi:10.1126/scisignal.2002355
66. Ghavami S, Cunnington RH, Yeganeh B, Davies JJ, Rattan SG, Bathe K, et al.
Autophagy regulates trans fatty acid-mediated apoptosis in primary cardiac
myofibroblasts. Biochim Biophys Acta (2012) 1823:2274–86. doi:10.1016/j.
bbamcr.2012.09.008
www.frontiersin.org March 2014 | Volume 5 | Article 37 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hombach-Klonisch et al. Mechanisms of therapeutic resistance in cancer
67. Debnath J, Baehrecke EH, Kroemer G. Does autophagy contribute to cell death?
Autophagy (2005) 1:66–74. doi:10.4161/auto.1.2.1738
68. Yorimitsu T, Klionsky DJ. Autophagy: molecular machinery for self-eating.Cell
Death Differ (2005) 12(Suppl 2):1542–52. doi:10.1038/sj.cdd.4401765
69. Lavieu G, Scarlatti F, Sala G, Levade T, Ghidoni R, Botti J, et al. Is autophagy
the key mechanism by which the sphingolipid rheostat controls the cell fate
decision? Autophagy (2007) 3:45–7.
70. Akalay I, Janji B, Hasmim M, Noman MZ, Andre F, De Cremoux P, et al.
Epithelial-to-mesenchymal transition and autophagy induction in breast
carcinoma promote escape from T-cell-mediated lysis. Cancer Res (2013)
73:2418–27. doi:10.1158/0008-5472.CAN-12-2432
71. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of
development and tumor metastasis. Dev Cell (2008) 14:818–29. doi:10.1016/j.
devcel.2008.05.009
72. Yang J, Wu LJ, Tashino S, Onodera S, Ikejima T. Reactive oxygen species and
nitric oxide regulate mitochondria-dependent apoptosis and autophagy in
evodiamine-treated human cervix carcinoma HeLa cells. Free Radic Res (2008)
42:492–504. doi:10.1080/10715760802112791
73. Akalay I, Janji B, Hasmim M, Noman MZ, Thiery JP, Mami-Chouaib F,
et al. EMT impairs breast carcinoma cell susceptibility to CTL-mediated lysis
through autophagy induction. Autophagy (2013) 9:1104–6. doi:10.4161/auto.
24728
74. Marcucci F, Bellone M, Caserta CA, Corti A. Pushing tumor cells towards
a malignant phenotype: stimuli from the microenvironment, intercellular
communications and alternative roads. Int J Cancer (2013). doi:10.1002/ijc.
28572
75. Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibit-
ing Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol (2011) 8:97–106.
doi:10.1038/nrclinonc.2010.196
76. Jimenez-Sanchez M, Menzies FM, Chang YY, Simecek N, Neufeld TP, Rubin-
sztein DC. The Hedgehog signalling pathway regulates autophagy. Nat Com-
mun (2012) 3:1200. doi:10.1038/ncomms2212
77. Fitzgerald JP, Nayak B, Shanmugasundaram K, Friedrichs W, Sudarshan S,
Eid AA, et al. Nox4 mediates renal cell carcinoma cell invasion through
hypoxia-induced interleukin 6- and 8- production. PLoS One (2012) 7:e30712.
doi:10.1371/journal.pone.0030712
78. Liu Y, Li H, Feng J, Cui X, Huang W, Li Y, et al. Lin28 induces epithelial-to-
mesenchymal transition and stemness via downregulation of Let-7a in breast
cancer cells. PLoS One (2013) 8:e83083. doi:10.1371/journal.pone.0083083
79. Diresta GR, Nathan SS, Manoso MW, Casas-Ganem J, Wyatt C, Kubo T, et al.
Cell proliferation of cultured human cancer cells are affected by the ele-
vated tumor pressures that exist in vivo. Ann Biomed Eng (2005) 33:1270–80.
doi:10.1007/s10439-005-5732-9
80. Abdullah L, Chow E-H. Mechanisms of chemoresistance in cancer stem cells.
Clin Transl Med (2013) 2:1–9. doi:10.1186/2001-1326-2-3
81. Lotze MT, Zeh HJ, Rubartelli A, Sparvero LJ, Amoscato AA, Washburn
NR, et al. The grateful dead: damage-associated molecular pattern molecules
and reduction/oxidation regulate immunity. Immunol Rev (2007) 220:60–81.
doi:10.1111/j.1600-065X.2007.00579.x
82. Suresh R, Mosser DM. Pattern recognition receptors in innate immunity,
host defense, and immunopathology. Adv Physiol Educ (2013) 37:284–91.
doi:10.1152/advan.00058.2013
83. Srikrishna G, Freeze HH. Endogenous damage-associated molecular pattern
molecules at the crossroads of inflammation and cancer. Neoplasia (2009)
11:615–28.
84. Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R, et al. HMGB1 promotes drug resis-
tance in osteosarcoma. Cancer Res (2012) 72:230–8. doi:10.1158/0008-5472.
CAN-11-2001
85. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P.
Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012)
12:860–75. doi:10.1038/nrc3380
86. Krysko O, Love Aaes T, Bachert C, Vandenabeele P, Krysko DV. Many faces
of DAMPs in cancer therapy. Cell Death Dis (2013) 4:e631. doi:10.1038/cddis.
2013.156
87. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol (2005)
17:1–14. doi:10.1093/intimm/dxh186
88. Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the
receptor for AGE (RAGE) as common soil in inflammation, immune responses
and diabetes mellitus and its complications. Diabetologia (2009) 52:2251–63.
doi:10.1007/s00125-009-1458-9
89. van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification
of toll-like receptor (TLR) and receptor for advanced glycation end products
(RAGE) signaling pathways via high mobility group B1 (HMGB1).Angiogenesis
(2008) 11:91–9. doi:10.1007/s10456-008-9093-5
90. Escamilla-Tilch M, Filio-Rodriguez G, Garcia-Rocha R, Mancilla-Herrera
I, Mitchison NA, Ruiz-Pacheco JA, et al. The interplay between pathogen-
associated and danger-associated molecular patterns: an inflammatory code
in cancer? Immunol Cell Biol (2013) 91:601–10. doi:10.1038/icb.2013.58
91. Kenny EF, O’Neill LA. Signalling adaptors used by toll-like receptors: an update.
Cytokine (2008) 43:342–9. doi:10.1016/j.cyto.2008.07.010
92. Kfoury A, Virard F, Renno T, Coste I. Dual function of MyD88 in inflammation
and oncogenesis: implications for therapeutic intervention. Curr Opin Oncol
(2014) 26:86–91. doi:10.1097/CCO.0000000000000037
93. Leclerc E, Fritz G,Vetter SW, Heizmann CW. Binding of S100 proteins to RAGE:
an update. Biochim Biophys Acta (2009) 1793:993–1007. doi:10.1016/j.bbamcr.
2008.11.016
94. Logsdon CD, Fuentes MK, Huang EH, Arumugam T. RAGE and RAGE
ligands in cancer. Curr Mol Med (2007) 7:777–89. doi:10.2174/
156652407783220697
95. Hudson BI, Kalea AZ, Del Mar Arriero M, Harja E, Boulanger E, D’Agati V, et al.
Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required
for ligand-stimulated cellular migration through activation of Rac1 and Cdc42.
J Biol Chem (2008) 283:34457–68. doi:10.1074/jbc.M801465200
96. Sakaguchi M, Murata H, Yamamoto K, Ono T, Sakaguchi Y, Motoyama
A, et al. TIRAP, an adaptor protein for TLR2/4, transduces a signal from
RAGE phosphorylated upon ligand binding. PLoS One (2011) 6:e23132.
doi:10.1371/journal.pone.0023132
97. Fritz G. RAGE: a single receptor fits multiple ligands.Trends Biochem Sci (2011)
36:625–32. doi:10.1016/j.tibs.2011.08.008
98. Sparvero LJ,Asafu-Adjei D, Kang R, Tang D,Amin N, Im J, et al. RAGE (receptor
for advanced glycation end products), RAGE ligands, and their role in cancer
and inflammation. J Transl Med (2009) 7:17. doi:10.1186/1479-5876-7-17
99. Metz VV, Kojro E, Rat D, Postina R. Induction of RAGE shedding by activa-
tion of G protein-coupled receptors. PLoS One (2012) 7:e41823. doi:10.1371/
journal.pone.0041823
100. Ostendorp T, Leclerc E, Galichet A, Koch M, Demling N, Weigle B, et al.
Structural and functional insights into RAGE activation by multimeric S100B.
EMBO J (2007) 26:3868–78. doi:10.1038/sj.emboj.7601805
101. Koch M, Chitayat S, Dattilo BM, Schiefner A, Diez J, Chazin WJ, et al. Struc-
tural basis for ligand recognition and activation of RAGE. Structure (2010)
18:1342–52. doi:10.1016/j.str.2010.05.017
102. Medapati M, Dahlmann M, Stein U, Ghavami S, Hombach-Klonisch S. S100A4
signaling in thyroid cancer. Experimental Biology Meeting. Boston: EB2013
(2013). 4052 p.
103. Kang R, Zhang Q, Zeh HJ III, Lotze MT, Tang D. HMGB1 in cancer: good, bad,
or both? Clin Cancer Res (2013) 19:4046–57. doi:10.1158/1078-0432.CCR-13-
0495
104. Conti L, Lanzardo S, Arigoni M, Antonazzo R, Radaelli E, Cantarella D, et al.
The noninflammatory role of high mobility group box 1/toll-like receptor 2 axis
in the self-renewal of mammary cancer stem cells. FASEB J (2013) 27:4731–44.
doi:10.1096/fj.13-230201
105. Riuzzi F, Sorci G, Donato R. The amphoterin (HMGB1)/receptor for advanced
glycation end products (RAGE) pair modulates myoblast proliferation, apop-
tosis, adhesiveness, migration, and invasiveness. Functional inactivation of
RAGE in L6 myoblasts results in tumor formation in vivo. J Biol Chem (2006)
281:8242–53. doi:10.1074/jbc.M509436200
106. Sorci G, Riuzzi F, Giambanco I, Donato R. RAGE in tissue homeostasis, repair
and regeneration. Biochim Biophys Acta (2013) 1833:101–9. doi:10.1016/j.
bbamcr.2012.10.021
107. Meneghini V, Francese MT, Carraro L, Grilli M. A novel role for the receptor
for advanced glycation end-products in neural progenitor cells derived from
adult subventricular zone. Mol Cell Neurosci (2010) 45:139–50. doi:10.1016/j.
mcn.2010.06.005
108. Taguchi A, Blood DC, Del Toro G, Canet A, Lee DC, Qu W, et al. Blockade
of RAGE-amphoterin signalling suppresses tumour growth and metastases.
Nature (2000) 405:354–60. doi:10.1038/35012626
Frontiers in Endocrinology | Thyroid Endocrinology March 2014 | Volume 5 | Article 37 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hombach-Klonisch et al. Mechanisms of therapeutic resistance in cancer
109. Hayakawa K, Pham LD, Katusic ZS, Arai K, Lo EH. Astrocytic high-mobility
group box 1 promotes endothelial progenitor cell-mediated neurovascu-
lar remodeling during stroke recovery. Proc Natl Acad Sci U S A (2012)
109:7505–10. doi:10.1073/pnas.1121146109
110. Hayakawa K, Pham LD,Arai K, Lo EH. High-mobility group box 1: an amplifier
of stem and progenitor cell activity after stroke. Acta Neurochir Suppl (2013)
118:31–8. doi:10.1007/978-3-7091-1434-6_5
111. Chavakis E, Hain A, Vinci M, Carmona G, Bianchi ME, Vajkoczy P, et al.
High-mobility group box 1 activates integrin-dependent homing of endothelial
progenitor cells. Circ Res (2007) 100:204–12. doi:10.1161/01.RES.0000257774.
55970.f4
112. Furlani D, Donndorf P, Westien I, Ugurlucan M, Pittermann E, Wang W, et al.
HMGB-1 induces c-kit+ cell microvascular rolling and adhesion via both toll-
like receptor-2 and toll-like receptor-4 of endothelial cells. J Cell Mol Med
(2012) 16:1094–105. doi:10.1111/j.1582-4934.2011.01381.x
113. Mardente S, Mari E, Consorti F, Di Gioia C, Negri R, Etna M, et al. HMGB1
induces the overexpression of miR-222 and miR-221 and increases growth
and motility in papillary thyroid cancer cells. Oncol Rep (2012) 28:2285–9.
doi:10.3892/or.2012.2058
114. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, et al. Toll-like receptors
on tumor cells facilitate evasion of immune surveillance. Cancer Res (2005)
65:5009–14. doi:10.1158/0008-5472.CAN-05-0784
115. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, et al.
TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in
ovarian cancer. Cancer Res (2006) 66:3859–68. doi:10.1158/0008-5472.CAN-
05-3948
116. Kawashima A, Yamazaki K, Hara T, Akama T, Yoshihara A, Sue M, et al.
Demonstration of innate immune responses in the thyroid gland: potential to
sense danger and a possible trigger for autoimmune reactions. Thyroid (2013)
23:477–87. doi:10.1089/thy.2011.0480
117. Hagstrom J, Heikkila A, Siironen P, Louhimo J, Heiskanen I, Maenpaa H,
et al. TLR-4 expression and decrease in chronic inflammation: indicators
of aggressive follicular thyroid carcinoma. J Clin Pathol (2012) 65:333–8.
doi:10.1136/jclinpath-2011-200402
118. Kim SK, Park HJ, Hong IK, Chung JH, Eun YG. A missense polymorphism
(rs11466653, Met326Thr) of toll-like receptor 10 (TLR10) is associated with
tumor size of papillary thyroid carcinoma in the Korean population. Endocrine
(2013) 43:161–9. doi:10.1007/s12020-012-9783-z
119. Lee SH, Hong B, Sharabi A, Huang XF, Chen SY. Embryonic stem cells and
mammary luminal progenitors directly sense and respond to microbial prod-
ucts. Stem Cells (2009) 27:1604–15. doi:10.1002/stem.75
120. Neal MD, Sodhi CP, Jia H, Dyer M, Egan CE, Yazji I, et al. Toll-like receptor
4 is expressed on intestinal stem cells and regulates their proliferation and
apoptosis via the p53 up-regulated modulator of apoptosis. J Biol Chem (2012)
287:37296–308. doi:10.1074/jbc.M112.375881
121. Cai Z, Sanchez A, Shi Z, Zhang T, Liu M, Zhang D. Activation of toll-like recep-
tor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor
growth. Cancer Res (2011) 71:2466–75. doi:10.1158/0008-5472.CAN-10-1993
122. Reeves R, Nissen MS. The AT-DNA-binding domain of mammalian high
mobility group I chromosomal proteins. A novel peptide motif for recognizing
DNA structure. J Biol Chem (1990) 265:8573–82.
123. Banks GC, Mohr B, Reeves R. The HMG-I(Y) AT-hook peptide motif confers
DNA-binding specificity to a structured chimeric protein. J Biol Chem (1999)
274:16536–44. doi:10.1074/jbc.274.23.16536
124. Berlingieri MT, Pierantoni GM, Giancotti V, Santoro M, Fusco A. Thyroid
cell transformation requires the expression of the HMGA1 proteins. Oncogene
(2002) 21:2971–80. doi:10.1038/sj.onc.1205368
125. Chiappetta G, Avantaggiato V, Visconti R, Fedele M, Battista S, Trapasso F, et al.
High level expression of the HMGI (Y) gene during embryonic development.
Oncogene (1996) 13:2439.
126. Rogalla P, Drechsler K, Frey G, Hennig Y, Helmke B, Bonk U, et al. HMGI-C
expression patterns in human tissues. Implications for the genesis of frequent
mesenchymal tumors. Am J Pathol (1996) 149:775.
127. Gattas GJ, Quade BJ, Nowak RA, Morton CC. HMGIC expression in human
adult and fetal tissues and in uterine leiomyomata. Genes Chromosomes
Cancer (1999) 25:316–22. doi:10.1002/(SICI)1098-2264(199908)25:4<316:
:AID-GCC2>3.0.CO;2-0
128. Györffy B, Surowiak P, Kiesslich O, Denkert C, Schäfer R, Dietel M, et al.
Gene expression profiling of 30 cancer cell lines predicts resistance towards
11 anticancer drugs at clinically achieved concentrations. Int J Cancer (2006)
118:1699–712. doi:10.1002/ijc.21570
129. Ben-Porath I, Thomson MW, CareyVJ, Ge R, Bell GW, Regev A, et al. An embry-
onic stem cell-like gene expression signature in poorly differentiated aggressive
human tumors. Nat Genet (2008) 40:499–507. doi:10.1038/ng.127
130. Disney JE, Johnson KR, Magnuson NS, Sylvester SR, Reeves R. High-mobility
group protein HMG-I localizes to G/Q- and C-bands of human and mouse
chromosomes. J Cell Biol (1989) 109:1975–82. doi:10.1083/jcb.109.5.1975
131. Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, van den Berghe H, Van
de Ven WJ. Recurrent rearrangements in the high mobility group protein
gene, HMGI-C, in benign mesenchymal tumours.NatGenet (1995) 10:436–44.
doi:10.1038/ng0895-436
132. Fedele M, Battista S, Kenyon L, Baldassarre G, Fidanza V, Klein-Szanto AJ, et al.
Overexpression of the HMGA2 gene in transgenic mice leads to the onset of
pituitary adenomas. Oncogene (2002) 21:3190–8. doi:10.1038/sj.onc.1205428
133. Finelli P, Pierantoni GM, Giardino D, Losa M, Rodeschini O, Fedele M, et al.
The high mobility group A2 gene is amplified and overexpressed in human
prolactinomas. Cancer Res (2002) 62:2398–405.
134. Hristov AC, Cope L, Di Cello F, Reyes MD, Singh M, Hillion JA, et al. HMGA1
correlates with advanced tumor grade and decreased survival in pancreatic duc-
tal adenocarcinoma. Mod Pathol (2009) 23:98–104. doi:10.1038/modpathol.
2009.139
135. Watanabe S, Ueda Y, Akaboshi S-I, Hino Y, Sekita Y, Nakao M. HMGA2 main-
tains oncogenic RAS-induced epithelial-mesenchymal transition in human
pancreatic cancer cells. Am J Pathol (2009) 174:854–68. doi:10.2353/ajpath.
2009.080523
136. Chau KY, Manfioletti G, Cheung-Chau KW, Fusco A, Dhomen N, Sowden JC,
et al. Derepression of HMGA2 gene expression in retinoblastoma is associated
with cell proliferation. Mol Med (2003) 9:154–65. doi:10.2119/2003-00020.
Ono
137. Dahlen A, Mertens F, Rydholm A, Brosjo O, Wejde J, Mandahl N, et al. Fusion,
disruption, and expression of HMGA2 in bone and soft tissue chondromas.
Mod Pathol (0000) 16:1132–40. doi:10.1097/01.MP.0000092954.42656.94
138. Di Cello F, Hillion J, Hristov A, Wood LJ, Mukherjee M, Schuldenfrei A, et al.
HMGA2 participates in transformation in human lung cancer. Mol Cancer Res
(2008) 6:743–50. doi:10.1158/1541-7786.MCR-07-0095
139. Belge G, Meyer A, Klemke M, Burchardt K, Stern C, Wosniok W, et al. Upregu-
lation of HMGA2 in thyroid carcinomas: a novel molecular marker to distin-
guish between benign and malignant follicular neoplasias. Genes Chromosomes
Cancer (2008) 47:56–63. doi:10.1002/gcc.20505
140. Lappinga PJ, Kip NS, Jin L, Lloyd RV, Henry MR, Zhang J, et al. HMGA2
gene expression analysis performed on cytologic smears to distinguish benign
from malignant thyroid nodules. Cancer Cytopathol (2010) 118:287–97.
doi:10.1002/cncy.20095
141. Cleynen I,Van de Ven WJ. The HMGA proteins: a myriad of functions (review).
Int J Oncol (2008) 32:289.
142. Pentimalli F, Palmieri D, Pacelli R, Garbi C, Cesari R, Martin E, et al. HMGA1
protein is a novel target of the ATM kinase. Eur J Cancer (2008) 44:2668–79.
doi:10.1016/j.ejca.2008.07.033
143. Palmieri D,Valentino T, D’Angelo D, De Martino I, Postiglione I, Pacelli R, et al.
HMGA proteins promote ATM expression and enhance cancer cell resistance
to genotoxic agents. Oncogene (2011) 30:3024–35. doi:10.1038/onc.2011.21
144. Lundholm L,Hååg P,Zong D, Juntti T,Mörk B,Lewensohn R,et al. Resistance to
DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells
involves reduced DNA-PK/ATM activation and diminished cell cycle arrest.
Cell Death Dis (2013) 4:e478. doi:10.1038/cddis.2012.211
145. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2
oncogene. Genes Dev (2007) 21:1025–30. doi:10.1101/gad.1540407
146. Copley MR, Babovic S, Benz C, Knapp DJ, Beer PA, Kent DG, et al. The
Lin28b-let-7-Hmga2 axis determines the higher self-renewal potential of
fetal haematopoietic stem cells. Nat Cell Biol (2013) 15:916–25. doi:10.1038/
ncb2783
147. Morishita A, Zaidi MR, Mitoro A, Sankarasharma D, Szabolcs M, Okada Y, et al.
HMGA2 is a driver of tumor metastasis. Cancer Res (2013) 73(14):4289–99.
doi:10.1158/0008-5472.CAN-12-3848
148. Guo L, Chen C, Shi M, Wang F, Chen X, Diao D, et al. Stat3-coordinated Lin-
28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin
M-driven epithelial-mesenchymal transition. Oncogene (2013) 32:5272–82.
doi:10.1038/onc.2012.573
www.frontiersin.org March 2014 | Volume 5 | Article 37 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hombach-Klonisch et al. Mechanisms of therapeutic resistance in cancer
149. Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin C-H, Mous-
takas A. Transforming growth factor-β employs HMGA2 to elicit
epithelial-mesenchymal transition. J Cell Biol (2006) 174:175–83. doi:10.1083/
jcb.200512110
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 11 February 2014; paper pending published: 04 March 2014; accepted: 11
March 2014; published online: 25 March 2014.
Citation: Hombach-Klonisch S, Natarajan S, Thanasupawat T, Medapati M, Pathak
A, Ghavami S and Klonisch T (2014) Mechanisms of therapeutic resistance in cancer
(stem) cells with emphasis on thyroid cancer cells. Front. Endocrinol. 5:37. doi:
10.3389/fendo.2014.00037
This article was submitted to Thyroid Endocrinology, a section of the journal Frontiers
in Endocrinology.
Copyright © 2014 Hombach-Klonisch, Natarajan, Thanasupawat ,Medapati, Pathak,
Ghavami and Klonisch. This is an open-access article distributed under the terms of the
Creative Commons Attribution License (CC BY). The use, distribution or reproduction
in other forums is permitted, provided the original author(s) or licensor are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Endocrinology | Thyroid Endocrinology March 2014 | Volume 5 | Article 37 | 10
